Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis

Author: Benzinga Newsdesk | April 16, 2024 03:46pm

Alvotech receives FDA approval for Selarsdi for moderate to severe plaque psoriasis

Adult patients with:

moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. (1.1)
active psoriatic arthritis (PsA). (1.2)

Pediatric patients 6 years and older with:

moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)

Posted In: ALVO